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Background: Experimental descriptions are typically stored as free text without using
standardized terminology, creating challenges in comparison, reproduction and
analysis. These difficulties impose limitations on data exchange and information
retrieval.
Results: The Ontology for Biomedical Investigations (OBI), developed as a global,
cross-community effort, provides a resource that represents biomedical investigations
in an explicit and integrative framework. Here we detail three real-world applications
of OBI, provide detailed modeling information and explain how to use OBI.
Conclusion: We demonstrate how OBI can be applied to different biomedical
investigations to both facilitate interpretation of the experimental process and
increase the computational processing and integration within the Semantic Web. The
logical definitions of the entities involved allow computers to unambiguously
understand and integrate different biological experimental processes and their
relevant components.
Availability: OBI is available at http://purl.obolibrary.org/obo/obi/2009-11-02/obi.owl
Background
Biomedical investigations use empirical approaches to investigate causal relationships
among a large range of variables. The wide range of possible investigations presents a
number of challenges when building tools to describe experimental processes. There
are varying levels of complexity and granularity and a wide range of material and
equipment is used. Furthermore, the use of varying terminology by different commu-
nities makes data integration problematic when representing and integrating biomedi-
cal investigations across different fields of study. The use of ontologies has been
successful in biological data integration and representation [1,2] and there have been
multiple efforts to develop ontologies aimed at providing clearer semantics for data
(GO, FuGO, MGED, EXPO, LABORS, MSI ontology) [3-8]. Work in the transcrip-
tomics, proteomics and metabolomics communities has proceeded in parallel, produ-
cing ontologies with overlapping scopes.
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reproduction in any medium, provided the original work is properly cited.Though each focuses on particular types of experimental processes, many terms,
such as investigation and assay, are common to all. Merging common aspects of these
formalisms is useful as it provides a mechanism by which terms can be used and
understood by all, reducing ambiguity and difficulties associated with post-hoc
attempts to integrate data. The practice of consolidating representations is endorsed by
organizations such as the OBO Foundry [9] which requires all member ontologies to
define a term only once among them (orthogonality). OBO Foundry members use a
common set of relations from the Relations Ontology [10], and the upper level Basic
Formal Ontology (BFO) [11] in order to facilitate cross ontology consistency and to
support automated reasoning [9]. OBO ontologies adhere to common naming conven-
tions [12] in order to make it easier to learn and understand them.
The Ontology for Biomedical Investigations (OBI) addresses the need for a cross-dis-
ciplinary, integrated ontology for the detailed description of biological and clinical
investigations. OBI is collaboratively developed by representatives from 19 biomedical
communities from around the globe and has been submitted as a candidate for the
OBO Foundry [9]. It uses other OBO ontologies wherever possible. OBI defines a set
of broadly applicable terms that span biomedical and technological domains, for
example, assay (the planned process of producing data about something) as well as
domain-specific terms relevant to smaller areas of study, for example, T cell epitope
recognition assay, used by the IEDB database to describe experimental data extracted
from articles investigating immune epitopes [13].
OBI represents all phases of experimental processes, and the entities involved in pre-
paring for, executing, and interpreting those processes e.g., study designs, protocols,
instrumentation, biological material, collected data and analyses performed on that
data. OBI also represents roles and functions used in biomedical investigations. OBI
therefore supports consistent annotation of biomedical experimental processes regard-
less of the field of study. OBI is expressed in OWL, a W3C ontology language devel-
oped for the Semantic Web. The development of OBI is driven by specific use cases of
experiments. In this paper, the OBI release of 2009-11-02 is applied to three exemplar
use cases, originating from three communities: 1) neuroscience, 2) vaccine protection,
and 3) functional genomics. The OBI release of 2009-11-02 is available at http://purl.
obolibrary.org/obo/obi/2009-11-02/obi.owl.
Results
In what follows, italics are used to refer to a specific term within OBI where appropri-
ate. OBI defines an investigation as a process with several parts, including planning an
overall study design, executing the designed study, and documenting the results. An
investigation typically includes interpreting data to draw conclusions.
Biomedical experimental processes involve numerous sub-processes, involving experi-
mental materials such as whole organisms, organ sections and cell cultures. These
experimental materials are represented as subclasses of the BFO class material entity.
OBI uses BFO’s material entity as the basis for defining physical things. Material entity
is an independent continuant, a continuant that is a bearer of quality and realizable
entity(s), in which other entities inhere and which itself cannot inhere in anything [11].
Material entities are entities that are spatially extended, whose identity is independent
of that of other entities, and which persist through time, for example organism, test
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are realized in the context of a process,e . g .study subject role, host role, specimen role,
patient role;a n dfunctions, results of design or evolution that depend on their physical
structure e.g. measure function, separation function and environment control function.
The function is considered to inhere in the material entity and be realized by the role
that material entity plays in a process.
To assess the completeness of the OBI release of 2009-11-02 and to demonstrate the
use of OBI for annotation, we present three representative use cases. These demon-
strate how to model entities and relations between entities involved in experimental
processes using OBI. The first use case models a neuroscience experiment described in
a journal article [14] and shows how logical definitions are constructed using parts of
external ontologies imported into OBI. The second use case details how OBI is used to
model vaccine studies; the third describes an investigation run by a Robot Scientist
which fully automatically designs and executes functional genomics experiments.
Use case 1: neuroscience investigation
This investigation studied the role of the primate caudate nucleus in the expectation of
reward following action [14]. While the caudate nucleus responds preferentially to eye
movements in different directions, the response begins prior to eye movement and is
dramatically increased when there is expectation of reward for the preferred direction.
Here we represent a single trial in which the visual target, a light, is presented to the
animal and the neural response is recorded as data. This single trial model contains
two processes (Figure 1):
1. Stimulating monkey with a light source, which is an example of presentation of
stimulus, having the participants Japanese macaque monkey as the subject and light
source as the stimulus, during the process of a measuring neural activity in the cau-
date nucleus assay.
2. Measuring neural activity in the caudate nucleus: this process is a subclass of the
process extracellular electrophysiology recording, which unfolds in the caudate
nucleus that is part of the Macaca fuscata, of which the Japanese macaque monkey
is an example. The anatomical term caudate nucleus is imported from the Neu-
roscience Information Framework standardized (NIFSTD) ontology [15] and used
in the logical definition of the assay.
The light on the tangent screen here is a light source used to present the stimulus to
the study subject. The function of the microelectrode, part of the single unit recorder
(an example of processed material), is realized in the measuring neural activity in the
caudate nucleus process. The process measuring neural activity in the caudate nucleus
has the specified input a neuron and the specified output a neuronal spike train datum.
Use case 2: vaccine protection investigation
A vaccine protection investigation (also known as a vaccine challenge experiment)
measures how efficiently a vaccine or vaccine candidate induces protection against a
virulent pathogen infection in vivo. Figure 2 demonstrates how to use OBI to represent
a typical vaccine protection investigation via the following three sub-processes:
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some material to be added role, borne by a vaccine (e.g., VacX) as well as a target
of material role borne by an organism that also bears a host role (e.g., mouse). The
term vaccination is a term imported from the Vaccine Ontology (VO, http://www.
violinet.org/vaccineontology). An injection function that inheres in a syringe (is a
processed material) is realized by the vaccination process.
2. A pathogen challenge is also a kind of administering substance in vivo process. It
realizes a number of roles - a pathogen role and material to be added role borne by
the challenge organism (e.g., Influenza Virus), and a target of material role and host
role borne by another organism (e.g., mouse). An injection function that inheres in
a syringeis realized by the pathogen challenge process.
3. A survival assessment is an assay that measures the survival rate (occurrence of
death events) in one or more organisms that are monitored over time. The survival
assessment is a protection efficiency assay that has specified input an u m b e ro f
Figure 1 OBI modeling of a single trial in the neuroscience study (a fragment). In this and
subsequent figures, boxes represent instances, labeled by the class they are instance of and relationships
as links labeled in italics. In several cases the parent class is also noted with the class label. Note that in
typical use only some instances would be explicitly created – others would be inferred as a consequent of
OBI’s definitions. Some processes in this experimental trial are presentation of stimulus, measuring neural
activity in the caudate nucleus, and stimulating monkey with light source. Some continuants are Macaca
fuscata, study subject role, spike train
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surement datum that records that 75% of mice survived the pathogen challenge.
Use case 3: an automated functional genomics investigation
The Robot Scientist “Adam” is designed to perform high-throughput growth curve
measurements (phenotypes) of selected microbial strains (genotypes) in a defined
media (environment) [7]. The robot requires a complete and precise description of all
experimental actions, and this use case demonstrates how OBI can be used to provide
elements of such a description. Here we have represented an investigation in which
Adam tests hypotheses about which metabolites can restore a function of the removed
yeast gene (Figure 3).
1. Adam’s planning yields a plan specification that has an objective specification to
test an inferred statements each of which are modeled as a hypothesis textual
entity. Each statement is about whether a particular metabolite will affect yeast
strain growth. Adam’s plan specifies an assay to test these hypotheses: to grow
yeast with and without addition of the metabolite.
2. The planned process of the automated investigation of the enzyme EC.6.1.39 is
an instance of the class hypothesis driven investigation with the objective to test the
hypothesis specified in the planning process (we represent here only a single
hypothesis textual entity which serves as a design pattern). The result is whether
the metabolite affected the growth of the yeast strain (see Figure 3, optical density
reading box). The upper growth curve (drawn in red) shows the growth rate with
the addition of the metabolite, and the lower curve (drawn in blue) shows the
growth rate with no metabolite. So, the addition of the metabolite affects the
Figure 2 OBI modeling of vaccine protection investigation (a fragment). Major processes are
vaccination and pathogen challenge, both of which are subtypes of administering substance in vivo. The
roles target of material addition and material to be added role are defined with respect to this parent
class. Some objects are syringe, mouse, host role, target of material addition role, VacX and a portion of
Influenza Virus. Note that while the figure shows a single input for the survival assessment, in fact there
would be many replicates of the experiment shown, with observations of mouse survival from all of them
input to the survival assessment.
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tual entity that states that the hypothesis inferred by Adam has been confirmed
and the robot can update its background knowledge.
3. The investigation process has several assays that provide data used to test the
hypotheses. The assay has specified inputs the metabolite and the yeast strain speci-
fied in the hypothesis,a n dt h especified output is a data set consisting of several
optical density measurements. The yeast bears the evaluant role, and the metabo-
lite the nutrient role.
Discussion
OBI was built to provide a comprehensive and versatile representation of biomedical
investigations. Our three biological use cases are represented by statements in terms
defined in OBI (see Tables 1 and 2). Individual experimental steps - the two processes
in the neuroscience use case, the three processes in the vaccine protection case, and
the three processes in the functional genomics case - all fall under planned process in
OBI.
In the example of the neuroscience investigation use case, the construction of logical
definitions of the experimental process encouraged us to ask questions of domain
experts because details we wished to capture were not explicit in the publication. For
example, was the location of the micro-electrode extra- or intra- cellular? Were all
spike train data recorded from the caudate nucleus? How does a spike train relate to
Figure 3 OBI modeling of the Robot Scientist automated investigation (a fragment). Major processes
are planning, automated investigation of the enzyme EC2.6.1.39, and the assay, while important objects are
the Robot Scientist Adam, an amount of yeast strain deltaYER152C, L-saccharopine, the optical density
reading data set.
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Classes Sources and term IDs Parent class Use
cases
administering substance in vivo OBI: OBI_0600007 material combination 2
assay OBI: OBI_0000070 planned process 1,3
caudate nucleus NeuroLex: birnlex_1373 anatomical entity 1
conclusion textual entity IAO: IAO_0000144 textual entity 3
data set IAO: IAO_0000100 data item 3
evaluant role OBI: OBI_0000067 role 3
extracellular electrophysiology
recording
OBI: OBI_0000454 assay 1
function snap#Function realizable entity 1,2
host role OBI: OBI_0000725 role 2
hypothesis driven investigation OBI: OBI_0000355 planned process 3
hypothesis textual entity IAO: IAO_0000415 textual entity 3
independent continuant snap#IndependentContinuant continuant
injection function OBI:OBI_0005246 function 2
interpreting data OBI: OBI_0000338 process 3
investigation OBI: OBI_0000066 planned process 3
light source OBI: OBI_0400065 processed material 1
Macaca fuscata NCBI_Taxon:
NCBITaxon_9542
organism 1
material combination OBI: OBI_0000652 planned process 2
material to be added role OBI: OBI_0000319 role 2
material entity snap#MaterialEntity Independent continuant 1,2,3
measure function OBI: OBI_0000453 function 1
measurement device OBI: OBI_0000832 processed material 1
measurement datum IAO: IAO_0000109 data item 1,2
measuring neural activity in the
caudate nucleus
OBI: OBI_0000812 extracellular electrophysiology
recording
1
micro electrode OBI: OBI_0000816 processed material 1
neuron FMA: FMA:54527 anatomical entity 1
objective specification IAO: IAO_0000005 directive information entity 3
organism OBI: OBI_0100026 material_entity 2
pathogen challenge OBI: OBI_0000712 administering substance in
vivo
2
pathogen role OBI: OBI_0000718 role 2
plan specification IAO: IAO_0000104 directive information entity 3
planning OBI: OBI_0000339 planned process 3
presentation of stimulus OBI: OBI_0000807 process 1
process span#Process processual entity 1,2,3
processed material OBI: OBI_0000047 material entity 1,2,3
role snap#Role realizable entity 1,2,3
Saccharomyces cerevisiae NCBI_Taxon:
NCBITaxon_4932
organism 3
spike train datum OBI: OBI_0000801 measurement datum 1
study subject role OBI: OBI_0000097 role 1
survival assessment OBI: OBI_0000699 assay 2
survival rate OBI: OBI_0000789 measurement datum 2
syringe OBI: OBI_0000422 processed material 2
target of material addition role OBI: OBI_0000444 role 2
vaccination VO: VO_0000002 administering substance in
vivo
2
vaccine VO: VO_0000001 material entity 2
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answers, we augmented OBI’s existing assays and imported several terms from external
ontologies, for example NIFSTD. When we needed relations that were not yet present
in OBI, rather than define them ourselves we used relations from ro_proposed (http://
obofoundry.org/cgi-bin/detail.cgi?ro_proposed). For example unfolds in specifies that
an occurrent (process) happens in a certain location (i.e., the assay of spike trains in
the caudate nucleus). Finally, we used the NCBI taxonomy [16] to describe the species
involved in this experiment. Re-use of external resources fulfils two purposes. First, as
domain experts have already devoted time to defining terms in these external ontolo-
gies we save ourselves substantial efforts by not replicating that work. Second, by
re-using existing resources that others already use, we improve the potential for future
data integration by making it unnecessary to map between different identifiers denot-
ing the same entity.
In developing the neuroscience use case we found decisions about choosing an
appropriate level of detail challenging: in this use case we decided not to include
instances of the classes, but instead to focus on adding classes that can be re-used for
other use cases and communities. It is our intention that our analysis and the classes
we defined serve as design patterns for other neuroscience assays. Depending on the
use case, OBI intends to be able to model the desired level of details (granularity),
from molecular level experiments to higher level of biomedical investigations. OBI can
be used at a more or less granular level depending on the user community needs.
In the second use case, the vaccine protection investigation includes three processes.
The processes vaccination and pathogen challenge are disjoint subclasses of administer-
ing substance in vivo. The process Survival assessment is a type of assay (Table 1). We
found that all these required processes, as well as all other entities described in the use
case could be represented using OBI idioms. Syringe is a processed material that parti-
cipates in different processes. Entities such as vaccine are types of material entity. Host
role, pathogen role, and material to be added role are types of role.
That OBI can be used to represent experimental processes for different applications
and domains is appealing because it suggests that we can better leverage the work we
each do. For the domain of vaccine investigation, approximately 400 vaccines have
been manually curated and stored in the Vaccine Investigation and Online Information
Table 2 Relations used in the three use cases:
Property terms Sources Use cases
bearer_of RO: OBO_REL#bearer_of 1,3
has_part ro.owl#has_part 3
has_participant ro.owl#has_participant 1
has_specified_input OBI: OBI_0000293 1,2,3
has_specified_output OBI: OBI_0000299 1,2,3
inheres_in RO: OBO_REL#inheres_in 1,2,3
is about IAO: IAO_0000136 3
is_a RO: OBO_REL:is_a 1,2,3
is_realized_by IAO: IAO_0000122 1, 2, 3
location_of ro.owl#location_of 1
part_of ro.owl#part_of 1
participates_in ro.owl#participates_in 3
unfolds_in RO: OBO_REL#unfolds_in 1
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Page 8 of 11Network (VIOLIN; http://www.violinet.org) vaccine database system [17]. Currently,
the vaccine protection experimental data in VIOLIN is stored in plain text and can be
difficult to interpret. The lack of a common ontology to aid in representing this data
has prevented optimal use of the VIOLIN vaccine data. We plan to apply the represen-
tation described in this paper to that data in order to enable advanced querying both
within the data as well as across data from other biomedical communities that repre-
sent their data using OBI. As an example, consider that a vaccine candidate against
Alzheimer disease may induce specific changes on the brains of transgenic mice or
human patients (http://www.ncbi.nlm.nih.gov/pubmed/12379846). Therefore enabling
queries across the domains of vaccinology and neuroscience would be of utility in con-
ducting such research.
The representations of the investigations run by Adam were stored as instances of
the defined classes in a relational database [18]. Accurate and complete recording of
all experimental processes involved in the investigations allows efficient re-use of pro-
duced data and results for different investigations with different objectives. OBI’s
approach to representation for automation suggests new possibilities for automated
investigations, desirable because such methods offer high throughput mechanisms not
only for data generation, but also for hypotheses generation and the results analysis.
As using terminology from a wide range of biology is a central part of OBI’s methodol-
ogy, we can easily imagine that it is reasonable to extend the reach of such an
approach. For example, DNA microarray experiments may also be performed using
Robot Scientists in order to generate and test hypotheses regarding the transcript
expression level in brain or other tissues, and knowledge encapsulated the Gene Ontol-
ogy or other ontologies could be applied to interpreting the results of such
experiments.
Conclusions
Here we provide three real world use cases as examples of how to represent experi-
mental processes with OBI. Experience such as this helps validate OBI’s current design
choices, as well show how to extend it in domain specific ways. It also generates com-
petency questions that allow us to identify parts of OBI that are insufficiently expres-
sive and to identify external resources that can be used to extend OBI’sc o v e r a g e .W e
found that a major technical challenge is the requirement to import terms from other
ontologies to construct logical definitions: due to its broad scope OBI spans multiple
existing ontological resources. There is a significant cost preventing those large
imports, as reasoning becomes slower and the ontology is harder to navigate. To solve
this problem the OBI consortium developed the MIREOT mechanism [19], which pre-
serves namespaces of imported terms and allows their direct use into OBI. We also
hope that technologies such as views [20] and modules [21] as well as improvements
to existing reasoners will address these issues. OBI will be further developed to expand
the coverage and depth of biomedical investigations and the use cases presented here
helped us in testing the version 1.0 of the ontology.
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